Oral antidiabetic drugs: Effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet

Journal of Clinical Pharmacology

Volumn 47, Issue 1, 2007, Pages 48-55

  Karim, Aziz ^a   Slater, Margaret ^a   Bradford, Dawn ^a   Schwartz, Lisa ^a   Laurent, Aziz ^b  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

Fixed dose combination tablets; Food effect; Metformin; Oral antidiabetic drugs; Pioglitazone

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; PIOGLITAZONE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG APPROVAL; DRUG FORMULATION; FEMALE; FOOD; HUMAN; LOOSE FECES; MALE; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; REGRESSION ANALYSIS; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; FOOD; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; LEAST-SQUARES ANALYSIS; MALE; METFORMIN; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 33845803595     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293756     Document Type: Article

References (21)

1. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000 ; 22: 1395-1409.
2. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005 ; 21: 167-174.
3. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002 ; 24: 460-467.
4. Mooradian AD. Towards single-tablet therapy for type 2 diabetes mellitus: rationale and recent developments. Treat Endocrinol. 2004 ; 3: 279-287.
5. Welling PG. Effect of food on drug absorption. Annu Rev Nutr. 1996 ; 16: 383-415.
6. Singh BN. Effect of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999 ; 37: 213-255.
7. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet. 1999 ; 36: 233-254.
8. Li Z, Vachharajani NN, Krishna R. On the assessment of effects of food on the pharmacokinetics of drugs in early development. Biopharm Drug Dispos. 2002 ; 23: 165-171.
9. ACTOS prescribing information, www.actos.com/pi.pdf.
10. Geerlof JS, Lebrizzi R, Carey RA. Effect of food on the pharmacokinetics of pioglitazone [abstract]. Diabetes. 2000 ; 49 (Suppl 1). A357 - A357.
11. Glucophage/Glucophage XR prescribing information, www.glucophagexr.com/ index.html.
12. Sambol NC, Brookes LG, Chiang J, et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol. 1996 ; 42: 510-512.
13. Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH. Pharmacokinetic and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol. 2000 ; 40: 1494-1502.
14. ACTOplus met prescribing information, www.actos.com/sub_sec8_about_plus. asp.
15. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, Md: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research ; December 2002.
16. Wright JG, Boddy AV. All half-lives are wrong, but some half-lives are useful. Clin Pharmacokinet. 2001 ; 40: 237-244.
17. Pentikanien PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979 ; 16: 195-202.
18. Cheng C-L, Yu L, Lee H-L, Yang C-Y, Lue C-S, Chou C-H. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. European J Pharm Sci. 2004 ; 22: 297-304.
19. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes. 2000 ; 108: S234 - S242.
20. Karim A. Importance of food effect studies early in drug development. In: Midha KK, Nagai T, eds. Bioavailability, Bioequivalence, and Pharmacokinetic Studies. Tokyo: Business Center for Academic Societies ; 1996: 221-229.
21. Karim A, Burns T, Janky D, Hurwitz A. Food-induced changes in theophylline absorption from controlled-release formulations. II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption. Clin Pharmacol Ther. 1985 ; 38: 642-647.